Zobrazeno 1 - 10
of 42
pro vyhledávání: '"James L. Orford"'
Publikováno v:
Catheterization and Cardiovascular Interventions. 96:219-224
Percutaneous patent foramen ovale (PFO) closure is recommended for secondary prevention of paradoxical embolism through a PFO. In the United States, two Food and Drug Administration-approved PFO closure devices are currently available, and the choice
Autor:
Jonathan White, Amar Krishnaswamy, Martin B. Leon, Samir R. Kapadia, Steven J. Yakubov, Daniel S. Menees, Stanley Chetcuti, John K. Forrest, Paul M. Grossman, Carlos E. Sanchez, James L. Orford, Tamim Nazif, Arash Arshi, Brian Whisenant, Susheel Kodali, Shmuel Chen, Jose Dizon, Pablo Codner
Publikováno v:
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventionsREFERENCES. 95(5)
Objectives This multicenter retrospective study of the initial U.S. experience evaluated the safety and efficacy of temporary cardiac pacing with the Tempo® Temporary Pacing Lead. Background Despite increasing use of temporary cardiac pacing with th
Autor:
Steven R. Steinhubl, Paula J. Santrach, Charles L. Campbell, David L. McGlassen, Mark H. Ereth, William C. Oliver, Lisa M. Schrader, James L. Orford, Greg A. Nuttall, Peter B. Berger, Christopher M. Thompson, M. Katie Murphy
Publikováno v:
American Heart Journal. 150:796-799
Background The active metabolite of clopidogrel binds the P2Y 12 ADP receptor on the platelet surface via a disulfide bond. N -Acetylcysteine (NAC) is able to reduce disulfide bonds. We postulated that NAC might reverse clopidogrel's effect on platel
Autor:
Peter B. Berger, David R. Holmes, James L. Orford, Ali E. Denktas, James T. Willerson, Brent A. Williams, Panayotis Fasseas
Publikováno v:
American Heart Journal. 148:501-506
Purpose The purpose of the current study was to determine whether there is any incremental benefit to routine intravascular ultrasound (IVUS) guidance of percutaneous coronary intervention. Methods and results We compared the outcome of 796 patients
Autor:
Dieter Lubbe, Peter M. DiBattiste, Peter B. Berger, Deepak R. Talreja, Ryan J. Lennon, James L. Orford
Publikováno v:
Journal of Thrombosis and Thrombolysis. 18:25-30
Introduction: While the CURE trial demonstrated the benefits of clopidogrel in acute coronary syndromes, patients receiving glycoprotein IIb/IIIa antagonists were excluded. Given the frequent coadministration of these two medications, we sought to ex
Publikováno v:
Journal of the American College of Cardiology. 43(8):1335-1342
Intravascular ultrasound (IVUS) has played an integral role in the evolution of interventional cardiology. However, routine IVUS guidance of coronary stent implantation is not supported by a critical reappraisal of the available evidence. Although th
Autor:
Peter B. Berger, Kelli N. Burger, Steven Melby, Panayotis Fasseas, David R. Holmes, Steven R. Steinhubl, James L. Orford
Publikováno v:
American Heart Journal. 147:463-467
Background Dual antiplatelet therapy with aspirin and clopidogrel has replaced aspirin and systemic anticoagulation with warfarin as the preferred antithrombotic therapy after percutaneous coronary intervention (PCI) with stent placement. However, a
Autor:
Ryan J. Lennon, David R. Holmes, Panayotis Fasseas, Ali E. Denktas, James L. Orford, Peter B. Berger, Carmelo J. Panetta, Malcolm R. Bell
Publikováno v:
American Heart Journal. 147:140-145
Background Coronary perforation is a serious but uncommon complication of percutaneous coronary intervention (PCI) and is associated with significant morbidity and mortality. Methods We performed an analysis of the Mayo Clinic PCI database. Clinical
Autor:
James L. Orford, Brian Whisenant
Publikováno v:
JACC: Cardiovascular Interventions. 9:2341-2342
Autor:
Peter B. Berger, Stephanie H. Wilson, Terese T. Horlocker, Panayotis Fasseas, Steven Melby, James L. Orford, Nina E Charnoff, Ryan J. Lennon
Publikováno v:
Journal of the American College of Cardiology. 42:234-240
OBJECTIVES We sought to determine the frequency and timing of complications at our institution when surgery was performed within two months of coronary stent placement. BACKGROUND The optimal delay following coronary stent placement prior to non-card